TechNavio's analysts forecast the Global Radio Pharmaceutical market to grow at a CAGR of 18.39 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Radio Pharmaceutical market has also been witnessing the increasing demand for radiopharmaceuticals. However, the short half-life could pose a challenge to the growth of this market.
TechNavio's report, the Global Radio Pharmaceutical Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Radio Pharmaceutical market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Cardinal Health Inc., Covidien plc, Lantheus Medical Imaging Inc., and IBA Molecular Inc.
Other vendors mentioned in the report are Advanced Medical Isotope Corp., Advanced Accelerator Applications SA, Algeta ASA, Bio-Nucleonics Inc., GE Healthcare Ltd., Monrol Nuclear Products Inc., Molecular Insight Pharmaceuticals Inc., Nordion Inc., Novelos Therapeutics Inc., NTP Radioisotopes (Pty) Ltd., Positron Corp., and Siemens Healthcare.
Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
01. Executive Summary
02. Scope of the Report
02.1 Market Overview
02.2 Product Offerings
03. Market Research Methodology
03.1 Market Research Process
03.2 Research Design
03.3 Research Methodology
04. List of Abbreviations
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Global Radiopharmaceuticals Market Segmentation by Application
07.1 Global Diagnostic Radiopharmaceuticals Market
07.1.1 Market Size and Forecast
07.2 Global Therapeutics Radiopharmaceuticals Market
07.2.1 Market Size and Forecast
08. Geographical Segmentation
09. Key Leading Countries
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2012
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 Covidien plc
18.1.1 Business Overview
18.1.2 Business Segmentation
18.1.3 Key Information
18.1.4 SWOT Analysis
18.2 Cardinal Health Inc.
18.2.1 Business Overview
18.2.2 Business Segmentation
18.2.3 Key Information
18.3 IBA Molecular Inc.
18.3.1 Business Overview
18.3.2 Business Segmentation
18.3.3 Key Information
18.3.4 SWOT Analysis
18.4 Lantheus Medical Imaging Inc.
18.4.1 Business Overview
18.4.2 Key Information
18.4.3 SWOT Analysis
19. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Radiopharmaceuticals Market 2012-2016 (US $ billion)
Exhibit 3: Global Radiopharmaceuticals Market Segmentation by Application
Exhibit 4: Global Radiopharmaceuticals Market Segmentation Based on Application 2012
Exhibit 5: Global Radiopharmaceuticals Market Segmentation Based on Application 2016
Exhibit 6: Global Diagnostic Radiopharmaceuticals Market 2012-2016 (US$ billion)
Exhibit 7: Global Therapeutics Radiopharmaceuticals Market 2012-2016 (US$ billion)
Exhibit 8: Global Radiopharmaceuticals Market by Geographical Segmentation 2012
Exhibit 9: Global Radiopharmaceuticals Market by Vendor Segmentation 2012
Exhibit 10: Business Segmentation of Covidien plc
Exhibit 11: Business Segmentation of Cardinal Healthcare Inc.
Exhibit 12: Business Segmentation of IBA Molecular Inc.